ACBI3
ACBI3 is a selective pan-KRAS degrader that potently eliminates oncogenic KRAS proteins. It demonstrates robust anti-proliferative activity in vitro against a broad range of KRAS-mutant cancer cell lines and has shown promising efficacy in vivo in preclinical tumor models, supporting its use in oncology and targeted protein degradation research.
Product Specifications
CAS Number
2938169-76-5
Product Name Alternative
KRAS, ACBI-3
Field of Research
Pharmacology & Drug Discovery, Signal Transduction
Purity
99.24% (May vary between batches)
Solubility
DMSO:200 mg/mL (196.22 mM)
Smiles
C[C@]1 (C2=C (SC (N) =C2C#N) CCC1) C3=NC (=NO3) C4=NC (=NC=C4) N5[C@@H] (C) CN (CCCCOC6=CN ([C@H] (C (=O) N7[C@H] (C (N[C@@H] (CO) C8=CC=C (C=C8) C=9SC=NC9C) =O) C[C@@H] (O) C7) C (C) C) N=N6) CCC5
Molecular Formula
C50H62N14O6S2
Molecular Weight
1019.25
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
132925-APC 100 µL
S100A6 (Protein S100-A6, S100 Calcium-binding Protein A6, Calcyclin, Prolactin Receptor-associated Protein, PRA, Growth Factor-inducible Protein 2A9, MLN 4, CACY) (APC)
Sign In for Pricing
View Details 
407153-01 50 µL
STAB2 (Stabilin-2, FAS1 EGF-like and X-link Domain-containing Adhesion Molecule 2, Fasciclin, EGF-like, Laminin-type EGF-like and Link Domain-containing Scavenger Receptor 2, FEEL-2, Hyaluronan Receptor for Endocytosis, STAB2)
Sign In for Pricing
View Details 407153-02 100 µL
STAB2 (Stabilin-2, FAS1 EGF-like and X-link Domain-containing Adhesion Molecule 2, Fasciclin, EGF-like, Laminin-type EGF-like and Link Domain-containing Scavenger Receptor 2, FEEL-2, Hyaluronan Receptor for Endocytosis, STAB2)
Sign In for Pricing
View Details